Ticovac

Ticovac is an inactivated vaccine for tick-borne encephalitis virus, Neudoerfl strain, designed to help prevent TBE infection. It is administered via intramuscular or subcutaneous injection. Suitable for travelers and residents in endemic regions. Short-term protection begins after the first dose.

Ticovac is used to protect against tick-borne encephalitis (TBE), a viral infection transmitted by ticks. It is commonly recommended for individuals traveling to or living in areas where TBE is prevalent. The vaccine helps the immune system recognize and fight the virus, reducing the risk of infection. It is also used for pre-exposure prophylaxis in high-risk groups.

After vaccination, the body begins building immunity against the tick-borne encephalitis virus. Common effects include mild soreness at the injection site, fatigue, or low-grade fever. These are typically temporary and indicate the immune system’s response to the vaccine. Most individuals tolerate the vaccine well without significant discomfort.

Ticovac should be stored refrigerated between 2°C and 8°C and protected from light. It is not recommended for individuals with a known allergy to any component of the vaccine. Before administration, inform your healthcare provider about any current illnesses or medications. Pregnant or breastfeeding individuals should consult a healthcare professional before use.

Ticovac may interact with immunosuppressive therapies, reducing its effectiveness. Concurrent use of other vaccines should be spaced appropriately unless advised otherwise by a healthcare provider. Alcohol and certain medications may influence immune response, though specific interactions are not well-documented. Always disclose all medications and conditions to your healthcare provider.